Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders
published in: Diabetes
date of publication: 2013-07-08
language: English
main subject: type-1 diabetes, randomized controlled trial
Cites articles 31
Date
Title
Article - wd:Q37251153